HansBiomed Corporation (042520) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HansBiomed Corporation (042520) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.21 Billion ≈ $817.15K USD) by net assets (₩33.89 Billion ≈ $22.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 042520 company net worth for the company's overall valuation and market capitalisation.
HansBiomed Corporation - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how HansBiomed Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
HansBiomed Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HansBiomed Corporation ranked by their cash flow conversion efficiency. Explore HansBiomed Corporation cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sarfati
TA:SRFT
|
-0.441x |
|
Thai Nakarin Hospital Public Company Limited
BK:TNH
|
0.022x |
|
5paisa Capital Ltd
NSE:5PAISA
|
-0.098x |
|
Amarc Resources Ltd.
V:AHR
|
0.137x |
|
UmweltBank AG
XETRA:UBK
|
-0.132x |
|
Pro-Dex Inc
NASDAQ:PDEX
|
0.086x |
|
Cheffelo AB
ST:CHEF
|
0.097x |
|
Unisys Corporation
NYSE:UIS
|
-0.133x |
Annual Cash Flow Conversion Efficiency for HansBiomed Corporation (2012–2025)
The table below shows the annual cash flow conversion efficiency of HansBiomed Corporation from 2012 to 2025. View HansBiomed Corporation (042520) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | ₩33.89 Billion ≈ $22.96 Million |
₩318.34 Million ≈ $215.73K |
0.009x | -64.14% |
| 2024-09-30 | ₩67.12 Billion ≈ $45.49 Million |
₩1.76 Billion ≈ $1.19 Million |
0.026x | +135.06% |
| 2023-09-30 | ₩49.95 Billion ≈ $33.85 Million |
₩-3.73 Billion ≈ $-2.53 Million |
-0.075x | +20.13% |
| 2022-09-30 | ₩45.63 Billion ≈ $30.93 Million |
₩-4.27 Billion ≈ $-2.89 Million |
-0.094x | +71.60% |
| 2021-09-30 | ₩44.45 Billion ≈ $30.12 Million |
₩-14.64 Billion ≈ $-9.92 Million |
-0.329x | -445.66% |
| 2020-09-30 | ₩60.34 Billion ≈ $40.89 Million |
₩5.75 Billion ≈ $3.90 Million |
0.095x | +3.88% |
| 2019-09-30 | ₩84.07 Billion ≈ $56.97 Million |
₩7.71 Billion ≈ $5.23 Million |
0.092x | +15.14% |
| 2018-09-30 | ₩65.30 Billion ≈ $44.26 Million |
₩5.20 Billion ≈ $3.53 Million |
0.080x | -23.50% |
| 2017-09-30 | ₩53.73 Billion ≈ $36.41 Million |
₩5.60 Billion ≈ $3.79 Million |
0.104x | +1642.90% |
| 2016-09-30 | ₩46.82 Billion ≈ $31.73 Million |
₩-316.10 Million ≈ $-214.22K |
-0.007x | -108.41% |
| 2015-09-30 | ₩43.16 Billion ≈ $29.25 Million |
₩3.47 Billion ≈ $2.35 Million |
0.080x | +53.45% |
| 2014-09-30 | ₩39.39 Billion ≈ $26.69 Million |
₩2.06 Billion ≈ $1.40 Million |
0.052x | -34.24% |
| 2013-09-30 | ₩29.31 Billion ≈ $19.86 Million |
₩2.33 Billion ≈ $1.58 Million |
0.080x | +27.45% |
| 2012-09-30 | ₩24.04 Billion ≈ $16.29 Million |
₩1.50 Billion ≈ $1.02 Million |
0.062x | -- |
About HansBiomed Corporation
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralize… Read more